Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2005, for eXegenics Inc. (Note: The input metadata referenced "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). The company historically operated as a drug discovery firm but has been unsuccessful in advancing research programs. Management is currently focused on redeploying residual assets and identifying potential business opportunities. As of August 11, 2005, the company had 16,266,618 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2005 | Six Months Ended June 30, 2005 | Balance Sheet (June 30, 2005) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss (Common Shareholders) | $(434,000) | $(959,000) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.06) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $8,117,000 |
| Restricted Cash | N/A | N/A | $175,000 |
| Total Assets | N/A | N/A | $9,347,000 |
| Total Liabilities | N/A | N/A | $160,000 |
| Net Cash Used in Operating Activities | N/A | $(617,000) | N/A |
Material Changes vs. Prior Period
- Operating Expenses: General and administrative expenses decreased by 14% ($76,000) for the three months ended June 30, 2005, compared to the same period in 2004. For the six-month period, expenses decreased by 39% ($514,000). Reductions were driven by lower director and officer insurance premiums, leased equipment costs, and professional fees.
- Net Loss: Net loss attributable to common shareholders improved (decreased) by $97,000 for the quarter and $534,000 for the six-month period compared to the prior year.
- Interest Income: Interest income increased to $50,000 for the quarter (from $29,000) and $90,000 for the six months (from $59,000), primarily due to higher interest rates.
- Reserve for Receivables: A $208,000 allowance was recorded in the second quarter for a subscription receivable from a former CEO (Dr. Ronald Goode) who failed to make a required interest payment.
Outlook, Risks, and Unusual Items
- Management Changes: On June 29, 2005, David E. Riggs resigned as President, CEO, and CFO. John A. Paganelli assumed interim roles, and Dr. David F. Hostelley was appointed CFO on July 1, 2005. A separation agreement with Mr. Riggs resulted in a $96,000 severance expense.
- Strategic Direction: The Board has established a committee to study strategic direction and identify business opportunities, as the company has been unsuccessful in advancing its drug discovery programs.
- Investment Liquidity: The company holds marketable securities in Intrac, Inc. stock valued at $1,003,000. These shares were not fully tradable as of June 30, 2005, but a registration statement was declared effective in July 2005, permitting resale.
- Legal Proceedings:
- Weiss Litigation: Dismissed with prejudice in April 2005.
- Labidi Proceeding: A former employee filed a lawsuit alleging discrimination and conversion of research materials. Mediation failed, and a trial is set for November 2005.
- Accounting Changes: The company is evaluating the impact of SFAS 123R (Share-Based Payment), with adoption expected effective January 1, 2006.
Investor Verification Checklist
- Verify the status of the Intrac, Inc. stock investment ($1.0M) and the timeline for its liquidation following the July 2005 registration effectiveness.
- Confirm the outcome of the Labidi litigation scheduled for trial in November 2005 and potential financial exposure.
- Monitor the strategic committee's progress in identifying new business opportunities or asset redeployment plans, given the lack of revenue.
- Review the subscription receivable from Dr. Goode to determine if the $208,000 reserve is sufficient or if further write-downs are necessary.
- Assess the company's cash runway given the burn rate of approximately $617,000 over six months and total cash of ~$8.3 million.